skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C‐Lock linker

Authors:
ORCiD logo [1];  [2];  [2];  [2];  [1];  [1];  [1];  [3];  [1];  [1];  [2]
  1. College of Pharmaceutical Sciences, Institute of Drug Metabolism and Pharmaceutical Analysis and Zhejiang Provincial Key Laboratory of Anti‐Cancer Drug Research Zhejiang University Hangzhou China
  2. Zova Biotherapeutics Inc Fuyang, Hangzhou China
  3. Noeantigen Therapeutics (HangZhou) Co., Ltd Hangzhou China
Publication Date:
Sponsoring Org.:
USDOE Office of Electricity Delivery and Energy Reliability (OE), Power Systems Engineering Research and Development (R&D) (OE-10)
OSTI Identifier:
1498574
Alternate Identifier(s):
OSTI ID: 1498575
Grant/Contract Number:  
2017YFC0908600; 81430081
Resource Type:
Published Article
Journal Name:
Cancer medicine
Additional Journal Information:
Journal Name: Cancer medicine Journal Volume: 8 Journal Issue: 4; Journal ID: ISSN 2045-7634
Publisher:
Wiley Blackwell (John Wiley & Sons)
Country of Publication:
United Kingdom
Language:
English

Citation Formats

Shi, Baoying, Wu, Min, Li, Zhaohui, Xie, Zhangming, Wei, Xiaoyue, Fan, Jiansheng, Xu, Yingchun, Ding, Ding, Akash, Sajid Hamid, Chen, Shuqing, and Cao, Sheldon. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C‐Lock linker. United Kingdom: N. p., 2019. Web. doi:10.1002/cam4.2066.
Shi, Baoying, Wu, Min, Li, Zhaohui, Xie, Zhangming, Wei, Xiaoyue, Fan, Jiansheng, Xu, Yingchun, Ding, Ding, Akash, Sajid Hamid, Chen, Shuqing, & Cao, Sheldon. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C‐Lock linker. United Kingdom. doi:10.1002/cam4.2066.
Shi, Baoying, Wu, Min, Li, Zhaohui, Xie, Zhangming, Wei, Xiaoyue, Fan, Jiansheng, Xu, Yingchun, Ding, Ding, Akash, Sajid Hamid, Chen, Shuqing, and Cao, Sheldon. Mon . "Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C‐Lock linker". United Kingdom. doi:10.1002/cam4.2066.
@article{osti_1498574,
title = {Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C‐Lock linker},
author = {Shi, Baoying and Wu, Min and Li, Zhaohui and Xie, Zhangming and Wei, Xiaoyue and Fan, Jiansheng and Xu, Yingchun and Ding, Ding and Akash, Sajid Hamid and Chen, Shuqing and Cao, Sheldon},
abstractNote = {},
doi = {10.1002/cam4.2066},
journal = {Cancer medicine},
number = 4,
volume = 8,
place = {United Kingdom},
year = {2019},
month = {2}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
DOI: 10.1002/cam4.2066

Citation Metrics:
Cited by: 1 work
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Conjugates of Small Molecule Drugs with Antibodies and Other Proteins
journal, January 2014


Understanding and exploiting 5T4 oncofoetal glycoprotein expression
journal, December 2014


Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
journal, February 2008

  • Stasi, Roberto; Evangelista, Maria Laura; Buccisano, Francesco
  • Cancer Treatment Reviews, Vol. 34, Issue 1
  • DOI: 10.1016/j.ctrv.2007.09.001

T-DM1 — an important agent in the history of breast cancer management
journal, August 2017


5T4 oncofetal antigen expression in ovarian carcinoma
journal, January 1995


Long-term Tumor Regression Induced by an Antibody-Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells
journal, December 2012


Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
journal, October 2004


Trophoblast glycoprotein recognised by monoclonal antibody 5T4 maps to human chromosome 6q14?q15
journal, April 1990

  • Boyle, J. M.; Grzeschik, K. H.; Heath, P. R.
  • Human Genetics, Vol. 84, Issue 5
  • DOI: 10.1007/BF00195819

Inotuzumab Ozogamicin: First Global Approval
journal, August 2017


Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management
journal, November 2017


Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates
journal, February 2006

  • Sutherland, May S. Kung; Sanderson, Russell J.; Gordon, Kristine A.
  • Journal of Biological Chemistry, Vol. 281, Issue 15
  • DOI: 10.1074/jbc.M510026200

Antibody drug conjugates: lessons from 20 years of clinical experience
journal, October 2016


Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery:  Effects of Linker Technology on Efficacy and Toxicity
journal, January 2006

  • Doronina, Svetlana O.; Mendelsohn, Brian A.; Bovee, Tim D.
  • Bioconjugate Chemistry, Vol. 17, Issue 1
  • DOI: 10.1021/bc0502917

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
journal, May 2017


5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma
journal, October 2016


Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging
journal, January 2014

  • Schumacher, Felix F.; Nunes, João P. M.; Maruani, Antoine
  • Org. Biomol. Chem., Vol. 12, Issue 37
  • DOI: 10.1039/C4OB01550A

In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios
journal, April 2015


Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma
journal, May 1994

  • Starzynska, T.; Marsh, Pj; Schofield, Pf
  • British Journal of Cancer, Vol. 69, Issue 5
  • DOI: 10.1038/bjc.1994.173

Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen
journal, March 2002

  • Shaw, David M.; Woods, Andrew M.; Myers, Kevin A.
  • Biochemical Journal, Vol. 363, Issue 1
  • DOI: 10.1042/bj3630137

5T4 oncofoetal antigen: an attractive target for immune intervention in cancer
journal, October 2016


Immunohistological distribution of 5T4 antigen in normal and malignant tissues
journal, January 1990

  • Southall, Pj; Boxer, Gm; Bagshawe, Kd
  • British Journal of Cancer, Vol. 61, Issue 1
  • DOI: 10.1038/bjc.1990.20

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
journal, October 2016


Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells
journal, May 2011


Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
journal, August 2015


Vaccination of castration-resistant prostate cancer patients with TroVax (MVA–5T4) in combination with docetaxel: a randomized phase II trial
journal, July 2013

  • Harrop, Richard; Chu, Franklin; Gabrail, Nashat
  • Cancer Immunology, Immunotherapy, Vol. 62, Issue 9
  • DOI: 10.1007/s00262-013-1457-z

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
journal, January 2017

  • Shapiro, Geoffrey I.; Vaishampayan, Ulka N.; LoRusso, Patricia
  • Investigational New Drugs, Vol. 35, Issue 3
  • DOI: 10.1007/s10637-016-0419-7

Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy
journal, September 2014

  • Tumey, L. Nathan; Charati, Manoj; He, Tao
  • Bioconjugate Chemistry, Vol. 25, Issue 10
  • DOI: 10.1021/bc500357n

Isolation and characterization of 5T4, a tumour-associated antigen
journal, January 1990

  • Hole, Nicholas; Stern, Peter L.
  • International Journal of Cancer, Vol. 45, Issue 1
  • DOI: 10.1002/ijc.2910450132

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer
journal, January 2018


Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
journal, January 2014


Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
journal, September 2014

  • Lyon, Robert P.; Setter, Jocelyn R.; Bovee, Tim D.
  • Nature Biotechnology, Vol. 32, Issue 10
  • DOI: 10.1038/nbt.2968

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
journal, March 2015

  • Maruani, Antoine; Smith, Mark E. B.; Miranda, Enrique
  • Nature Communications, Vol. 6, Issue 1
  • DOI: 10.1038/ncomms7645

Antibody-drug conjugates—an emerging class of cancer treatment
journal, January 2016

  • Diamantis, Nikolaos; Banerji, Udai
  • British Journal of Cancer, Vol. 114, Issue 4
  • DOI: 10.1038/bjc.2015.435

Drug-conjugated antibodies for the treatment of cancer: Antibody-drug conjugates
journal, July 2013

  • Lambert, John M.
  • British Journal of Clinical Pharmacology, Vol. 76, Issue 2
  • DOI: 10.1111/bcp.12044